Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2007-02-08
2010-06-22
Mertz, Prema (Department: 1646)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C435S326000
Reexamination Certificate
active
07741450
ABSTRACT:
Hybridoma lines that secrete human monoclonal antibodies with high binding specificity and biological activity, particularly neutralizing activity against granulocyte-macrophage colony stimulating factor, and methods of generating the hybridoma lines are provided. Target antigens and epitopes are also provided. The antibodies may be used in therapeutic methods, for example in the treatment of cancer, infectious disease, or autoimmune disease.
REFERENCES:
patent: 5164369 (1992-11-01), Cochrane et al.
patent: 5260273 (1993-11-01), Cochrane et al.
patent: 5407914 (1995-04-01), Cochrane et al.
patent: 5602007 (1997-02-01), Dunn et al.
patent: 5789381 (1998-08-01), Cochrane et al.
patent: 5891429 (1999-04-01), Clark et al.
patent: 5952303 (1999-09-01), Bornstein et al.
patent: 6013619 (2000-01-01), Cochrane et al.
patent: 6013764 (2000-01-01), Abdel-Magid et al.
patent: 6120795 (2000-09-01), Klimchak et al.
patent: 6135430 (2000-10-01), Bergman, Jr. et al.
patent: 6498027 (2002-12-01), Van Es et al.
patent: 6613734 (2003-09-01), Cochrane et al.
patent: 7108852 (2006-09-01), Devalaraja et al.
patent: 2002/0010126 (2002-01-01), Hamilton et al.
patent: 2004/0053365 (2004-03-01), Renner et al.
patent: 2006/0257359 (2006-11-01), Francois et al.
patent: 0499161 (1992-08-01), None
patent: 1593690 (2005-11-01), None
patent: 1598419 (2005-11-01), None
patent: WO 89/06657 (1989-07-01), None
patent: WO 92/22315 (1992-12-01), None
patent: WO 98/49191 (1998-11-01), None
patent: WO 03/068924 (2003-08-01), None
patent: WO2004/046330 (2004-06-01), None
patent: WO2005/014652 (2005-02-01), None
patent: 2006111353 (2006-10-01), None
patent: 2006122797 (2006-11-01), None
patent: 2007-049472 (2007-05-01), None
patent: 2006/111353 (2008-01-01), None
Fleetwood, A.J., et al., “Functions of granulocyte-macrophage colony-stimulating factor,” Immunology, 2005, 25(5), 405-427.
Jian Li, et al., “Human antibodies for immunotherapy development generated via a human B cell hybridoma technology,” PNAS, 2006, 103(10), 3557-3562.
Yuzuru Kanakura, et al., “Identification of functionally distinct domains of human granulocyte-macrophage colony-stimulating factor using monoclonal antibodies,” Blood, 1991, 77(5), 1033-1043.
Argani, P., et al., “Mesothelin is overexpressed in the vast majority of ductial adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE),” Clin. Cancer Res., 2001, 7, 3862 3868.
Baritaki, S., et al., “Generation of human anti-MUC3 lgG antibodies after in vitro immunization of naïve peripheral blood B-lymphocytes,” Cancer Immunol. Immunother., 2001, 50, 109-114.
Beffy, P., et al., “An immunodominant epitope in a functional domain near the N-terminus of human granulocyte-macrophage colony-stimulating factor identified by cross-reaction of synthetic peptides with neutralizing anti-protein and anti-peptide antibodies,” Hybridoma, 1994, 13(6), 457-468.
Bischof, R.J., et al., “Exacerbation of acute inflammatory arthritis by the colony-stimulating factors CSF-1 and granulocyte macrophage (GM)-CSF: evidence of macrophage infiltration and local proliferation,” Clin. Exp. Immunol., 2000, 119, 361-367.
Blake, C., et al., “Stepwise deletions of polyA sequences in mismatch repair-deficient colorectal cancers,”An. J. Pathol., 2001, 158(5), 1867-1870.
Boerner, P., et al., “Production of antigen-specific human monoclonal antibodies from in vitro-primed human splenocytes,” J. Immunol., 1991, 147, 86-95.
Bonfield, T.L., et al., “Anti-GM-CSF titer predicts response to GM-CSF therapy in pulmonary alveolar proteinosis,” Clin. Immunol., 2002, 105(3), 342-350.
Burgess, A.W., et al., “The nature and action of granulocyte-macrophage colony stimulating factors,” Blood, 1980, 56(6), 947-958.
Burgress, A.W., et al., “Purification and properties of colony-stimulating factor from mouse lung-conditioned medium,” J. Biol. Chem., 1977, 252(6), 1998-2003.
Campbell, I.K., et al., “Granulocyte-macrophage colony stimulating factor exacerbates collagen induced arthritis in mice,” Ann. Rheum. Dis., 1997, 56, 364-368.
Campbell, I.K., et al., “Protection from collagen-induced arthritis in granulocyte-macrophage colony-stimulating,” J. of Immunol., 1998, 161, 3639-3644.
Chang, K., et al., “Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers,” Proc. Natl. Acad. Sci. USA, 1996, 93, 136-140.
Chothia, C., et al., “Canonical structures for the hypervariable regions of immunoglobulins,” J. Mol. Biol., 1987, 196, 901-917.
Cook, A.D., et al., “Blockade of collagen-induced arthritis post-onset by antibody to granulocyte-macrophage colony-stimulating factor (GM-CSF): requirement for GM-CSF in the effector phase of disease,” Arthritis Res., 2001, 3, 293-298.
Creighton, T.E., “Structures and Molecular Principles,”Proteins, 1984, index only, 4 pages.
Dempsey, P.J., et al., “Monoclonal antibodies that recognize human granulocyte-macrophage colony-stimulating factor and neutralize its bioactivity in vitro,” Hybridoma, 1990, 9(6), 545-558.
De Vries, e.G.E., et al., “Flare-up of rheumatoid arthritis during GM-CSF treatment after chemotherapy,” The Lancet, 1991, 338, 517-518.
Eisenbarth, S.C., et al., “Lipopolysaccharide-enhanced, toll-like receptor 4-dependent T helper cell type 2 responses to inhaled antigen,” J. Exp. Med., 2002, 196(12), 1645-1651.
Emanuel, P.D., “Juvenile myelomonocytic leukemia,” Curr. Hematol. Rep., 2004, 3, 203-209.
Emanuel, P.D., et al., “Selective hypersensitivity to granulocyte-macrophage colony-stimulating factor by juvenile chronic myeloid leukemia hematopoietic progenitors,” Blood, 1991, 77(5), 925-929.
Foote, J., et al., “Antibody framework residues affecting the conformation of the hypervariable loops,” J. Mol. Biol., 1992, 224, 487-499.
Gadi, V.K., et al., “In vivo sensitization of ovarian tumors to chemotherapy by expression ofE. colipurine nucleoside phosphorylase in a small fraction of cells,” Gene Ther., 2000, 7, 1738-1743.
Gajewska, B.U., et al., “GM-CSF and dendritec cells in allergic airway inflammation: basic mechanisms and prospects for therapeutic intervention,” Curr. Drug Targets Inflamm. Allergy, 2003, 2, 279-292.
Gamble, J.R., et al., “Stimulation of the adherence of meutrophils to umbilical vein endothelium by human recombinant tumor necrosis factor,” Proc. Natl. Acad. Sci. USA, 1985, 82, 8667-8671.
Garmestani, K., et al., “Synthesis and evaluation of a macrocylclic bifunctional chelating agent for use with bismuth radionucleides,” Nucl. Med. Biol., 2001, 28, 409-418.
Grasso, L., et al., “Enhancing therapeutic antibodies and titer yields of mammalian cell lines,” Bioprocess Int., 2004, 2, 58-64.
Hamilton, J.A., et al., “Stimulation of macrophage plasminogen activator activity by colony-stimulating factors,” J. of Cellular Physiology, 1980, 103, 435-445.
Hamilton, J.A., “Colony stimulating factors, cytokines and monocyte-macrophages—some controversies,” Immunol. Today, 1993, 14, 18-24.
Hamilton, J.A., “Rheumatoid arthritis: opposing actions of haemopoietic growth factors and slow-acting anti-rheumatic drugs,” Lancet, 1993, 342, 536-539.
Hamilton, “GM-CSF in inflammation and autoimmunity,” Trends in Immunol., 2002, 23(8), 403-408.
Handman, E., et al., “Stimulation by granulocyte-macrophage colony—stimulating factor ofLeishmania tropicakilling by macrophages,” J. Immunol., 1979, 122(3), 1134-1137.
Hassan, R., et al., “Mesothelin: a new target for immunotherapy,” Clin. Cancer Res., 2004, 10, 3937-3942.
Hart, P.H., et al., “Synergistic activation of human monocytes by granulocy
Chao Qimin
Ebel Wolfgang
Grasso Luigi
Li Jian
Nicolaides Nicholas C.
Mertz Prema
Morphotek Inc.
Woodcock & Washburn LLP
LandOfFree
Antibodies to GM-CSF does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antibodies to GM-CSF, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antibodies to GM-CSF will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4248471